.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
UBS
Chubb
Healthtrust
Queensland Health
Farmers Insurance
Harvard Business School
Johnson and Johnson
AstraZeneca
Deloitte

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,645,988

« Back to Dashboard

Which drugs does patent 6,645,988 protect, and when does it expire?


Patent 6,645,988 protects ZEGERID OTC, ZEGERID, and MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE, and is included in four NDAs. There have been zero Paragraph IV challenges on Zegerid OTC and Zegerid

This patent has sixty-two patent family members in twenty-four countries.

Summary for Patent: 6,645,988

Title: Substituted benzimidazole dosage forms and method of using same
Abstract:The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.
Inventor(s): Phillips; Jeffrey O. (Ashland, MO)
Assignee: Curators of the University of Missouri (Columbia, MO)
Application Number:09/901,942
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Healthcare LlcZEGERID OTComeprazole; sodium bicarbonateCAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► SubscribeYY► Subscribe
Santarus IncZEGERIDomeprazole; sodium bicarbonateFOR SUSPENSION;ORAL021636-001Jun 15, 2004ABRXYesNo► Subscribe► SubscribeYY► Subscribe
Santarus IncZEGERIDomeprazole; sodium bicarbonateFOR SUSPENSION;ORAL021636-002Dec 21, 2004ABRXYesYes► Subscribe► SubscribeYY► Subscribe
SantarusZEGERIDmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET, CHEWABLE;ORAL021850-001Mar 24, 2006DISCNNoNo► Subscribe► SubscribeYYSHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS► Subscribe
SantarusZEGERIDmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET, CHEWABLE;ORAL021850-002Mar 24, 2006DISCNNoNo► Subscribe► SubscribeYYSHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER► Subscribe
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-001Dec 4, 2009DISCNNoNo► Subscribe► SubscribeY► Subscribe
SantarusMAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATEmagnesium hydroxide; omeprazole; sodium bicarbonateTABLET;ORAL022456-002Dec 4, 2009DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,645,988

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,399,772Substituted benzimidazole dosage forms and method of using same► Subscribe
5,840,737 Omeprazole solution and method for using same► Subscribe
RE45198Omeprazole solution and method for using same► Subscribe
6,780,882 Substituted benzimidazole dosage forms and method of using same► Subscribe
6,699,885 Substituted benzimidazole dosage forms and methods of using same► Subscribe
6,489,346 Substituted benzimidazole dosage forms and method of using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,645,988

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Eurasian Patent Organization200400154► Subscribe
Brazil0210971► Subscribe
Brazil0306965► Subscribe
Canada2396159► Subscribe
Canada2453117► Subscribe
Canada2473669► Subscribe
Australia2003214858► Subscribe
Australia2005229686► Subscribe
Brazil0107565► Subscribe
Eurasian Patent Organization200400966► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Dow
QuintilesIMS
Harvard Business School
Teva
AstraZeneca
Fish and Richardson
Chinese Patent Office
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot